The honest line

The metabolic side of endometriosis — one pillar, not a cure

Two truths have to be held at the same time here. Drop either one and the whole picture goes wrong.

Havelle editorial · Education only, not medical advice · Reviewed July 2026

There is an honest conversation to be had about weight, insulin, and inflammation when you live with endometriosis — and there is a dishonest one that overpromises. The difference between them is a single line, and this piece exists to hold that line clearly. So let us state both truths up front, because the danger is always in keeping only one.

The line we never cross: GLP-1 medications, including compounded tirzepatide, are not a treatment for endometriosis. Endometriosis is an estrogen-driven inflammatory disease. There is no evidence these medications treat its lesions, shrink its tissue, or relieve its pain. Nothing here is a therapy for the condition.

Why the metabolic side still deserves attention

With that line firmly drawn, the other truth: your whole body deserves care, and metabolic health is part of it. Living with a chronic inflammatory condition, managing weight, and navigating insulin all touch how you feel day to day. Attending to them — thoughtfully, and without magical thinking — is a legitimate part of whole-woman care. It simply belongs alongside endometriosis-specific treatment, not in place of it.

What “one pillar” actually means

Picture your care as several pillars standing side by side. One is the endometriosis-specific treatment you pursue with a gynecologist or specialist — the pillar that addresses the disease itself. Another is metabolic and weight care, which supports the body around the disease. A GLP-1 medication, where a clinician judges it appropriate, sits in that second pillar. It can support weight and metabolic health for the whole person. It never touches the first pillar, and any provider who blurs the two is selling you something.

Care for the body around the disease is real work. Pretending it is care for the disease is not.

How to hold both at once

Holding both truths sounds harder than it is. In practice it looks like a provider who takes your weight and insulin seriously and says plainly that none of it treats your endo — who never offers a metabolic plan as a substitute for gynecologic care, and never lets “just lose weight” stand in for listening. That combination — serious about the whole body, honest about the limits — is exactly what the Whole-Woman Charter is built to measure.

A note on the medication itself. Much telehealth tirzepatide is compounded at a 503A pharmacy; compounded medications are not FDA-approved and are not reviewed by the FDA for safety or efficacy. Whether any of this is right for you is a decision for a licensed clinician who knows your full history. Nothing here is medical advice.

The reason to get this framing right is not caution for its own sake. It is that you deserve care that is honest in both directions — serious enough to attend to your whole body, and truthful enough to never dress metabolic support up as a cure it is not.

See who takes the whole body seriously →